Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Unilateral Intratympanic PIPE-505 in Subjects With Sensorineural Hearing Loss Associated With Speech-in-Noise Impairment

NCT04462198 is registered in ClinicalTrials.gov with Contineum Therapeutics as lead sponsor.

NCT NCT04462198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Unilateral Intratympanic PIPE-505 in Subjects With Sensorineural Hearing Loss Associated With Speech-in-Noise Impairment
Lead sponsor
Contineum Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
October 15, 2020
Completion date
June 17, 2021
Enrollment
28 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sensorineural hearing loss